Skip to content
Home/Companies/Biotech/Rathlin Therapeutics

Rathlin Therapeutics

Biotech·United Kingdom·Active·3yr hold
Entry
2023
Hold
3yr
Status
Active

Who owns Rathlin Therapeutics?

Rathlin Therapeutics is currently owned by Columbus Venture Partners through Columbus Life Sciences Fund IV (2023 vintage), since 2023.

Hand-verified · updated 2026-08-09

Columbus Venture Partners
Investor
Columbus Venture Partners
Columbus Life Sciences Fund IV · 2023 · Life Sciences VC

Key facts

HQUnited Kingdom
SectorBiotech
StatusActive

More from Columbus Life Sciences Fund IV

Other portfolio companies in the same fund.

Accipiter Biosciences
Accipiter Biosciences
Active
BiotechUnited States· 2025
DeepUll
Active
HealthTechSpain· 2025
Quibim
Active
HealthTechSpain· 2025
Advanthera
Advanthera
Active
PharmaSpain· 2024
Aleta Biotherapeutics
Aleta Biotherapeutics
Active
BiotechUnited States· 2024
Cocoon Bioscience
Cocoon Bioscience
Active
BiotechSpain· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Rathlin Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Rathlin Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue